Operating
Stemcentrx Impairment Charge
Agilent Technologies Stemcentrx Impairment Charge remained flat by 0.0% to $3.75M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 21.1%, from $4.75M to $3.75M. Over 4 years (FY 2021 to FY 2025), Stemcentrx Impairment Charge shows an upward trend with a 65.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2016
Last reportedQ4 2025Dec 22, 2025
Metric ID:
abbv_stemcentrx_impairmentHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $2M | $0 | $277M | $19M | $15M |
| YoY Change | — | -100.0% | — | -93.1% | -21.1% |
Range$0 – $277M
CAGR+65.5%
Avg YoY Growth-71.4%
Median YoY Growth-93.1%
Current Streak2+ years decline
Stemcentrx Impairment Charge at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's stemcentrx impairment charge?
- Agilent Technologies (A) reported stemcentrx impairment charge of $3.75M in Q3 2025.
- How has Agilent Technologies's stemcentrx impairment charge changed year-over-year?
- Agilent Technologies's stemcentrx impairment charge decreased by 21.1% year-over-year, from $4.75M to $3.75M.
- What is the long-term trend for Agilent Technologies's stemcentrx impairment charge?
- Over 4 years (2021 to 2025), Agilent Technologies's stemcentrx impairment charge has grown at a 65.5% compound annual growth rate (CAGR), from $2M to $15M.